The Fidelity Paradox in Spinal Cord Injury: Reframing Biomechanical Mimicry and Neurobiological Relevance for Clinical Translation Authors: Liang Cao, Wenjun Pi, Yanjun Zhang, V. Wee Yong, Mengzhou Xue Published: 2026 ABSTRACT ABSTRACTBackgroundDespite abundant neuroprotective successes in rodents, effective clinical therapies for spinal cord injury (SCI) remain elusive. This translational disconnect stems from a fidelity paradox. The over‐reliance on rodent models that achieve biomechanical mimicry of human trauma but lack fundamental biological equivalence.MethodsWe evaluated how physical simulation masks critical interspecies divergences. Following PRISMA guidelines, we systematically searched PubMed and Web of Science (2000–2024) to assess preclinical model utilization frequencies and synthesized evidence across distinct pathophysiological pillars to evaluate cross‐species biological mismatches.ResultsOur analysis reveals profound spatiotemporal dissonances across three pillars: (i) immunodynamics, where the delayed inflammatory resolution in mice misaligns with human chronobiology; (ii) lesion architecture, distinguishing rodent cystic cavitation from the fibrotic scarring characteristic of human pathology; and (iii) neural circuitry, contrasting indirect rodent corticospinal projections with the direct cortico‐motoneuronal connections essential for human dexterity. To address this, we propose a mechanistic fidelity matching framework. This paradigm shifts from indiscriminate single‐model validation to a problem‐driven matrix, selecting models based on their specific biological fidelity to targeted mechanisms—utilizing mice for scar modulation, rats for cystic repair, and nonhuman primates for fine sensorimotor recovery.ConclusionRestoring translational credibility requires replacing the pursuit of a universal model with a hierarchical, cross‐species validation pipeline anchored in objective, mechanism‐coupled readouts. Abbreviations Basso‐Beattie‐Bresnahan corticospinal tract mechanistic fidelity matching nonhuman primates Preferred Reporting Items for Systematic Reviews and Meta‐analyses spinal cord injury Introduction Spinal cord injury (SCI) is one of the most devastating conditions in neuroscience, inflicting permanent disability upon millions of patients worldwide and imposing a heavy socioeconomic burden [1, 2, 3]. Over the past few decades, basic research has unraveled the complex pathophysiological cascades following SCI at an unprecedented rate. This has led to numerous neuroprotective and axon‐regenerative strategies that have demonstrated remarkable efficacy in animal models, continuously fueling hope for clinical translation [4, 5, 6, 7]. However, the translational dilemma from bench to bedside has become a disquieting norm in the SCI field. Countless therapies that showed potent restorative potential in animal models have repeatedly failed in human clinical trials [8, 9, 10]. While multifactorial issues—including suboptimal clinical trial design or patient heterogeneity—undoubtedly contribute to individual translational setbacks, the widespread and systemic nature of these failures points more fundamentally toward a critical flaw in the validity of our preclinical research paradigm. It compels us to re‐evaluate the cornerstone of our research: the fidelity with which animal models of SCI recapitulate human pathology. A growing body of evidence indicates that the root of the problem lies in the biological chasm between species [11, 12]. Study show that the glial scar, which forms rapidly in rodents post‐injury, differs significantly in structure and function from the chronic scar in humans [13]. Concurrently, the response patterns of the immune system, particularly, the activation states of microglia and macrophages, do not fully align with those observed in human patients [14]. These disparities ultimately result in preclinical models that, while morphologically simulating the trauma, diverge from the human clinical condition at the level of key pathophysiological mechanisms. Therefore, this review will first deconstruct the existing toolbox of SCI animal models, delineating their respective strengths and limitations in physically simulating human injury. We will then elucidate the critical, and often profound, biological differences between current models and human pathology from three core perspectives: the temporal mismatch in inflammatory dynamics, structural differences in the reparative microenvironment, and innate disparities in neural circuit anatomy. Finally, to move beyond the current impasse, we introduce the mechanistic fidelity matching (MFM) framework. This paradigm shifts the focus from seeking a single perfect species to selecting models based on their biological alignment with specific therapeutic targets—scarring, regeneration, or circuitry—thereby restoring predictive validity to preclinical trials. The Current Paradigm: A Flawed Toolbox Prioritizing Physical Form Over Biological Fidelity To effectively investigate the complex pathophysiology of SCI (Figure S1) and evaluate potential therapies at the preclinical stage, a diverse array of animal models has been established [15, 16, 17]. Here, we summarize the common SCI induction methods used in nine key species: mice, rats, guinea pigs, rabbits, cats, dogs, pigs, nonhuman primates (NHPs), and zebrafish (Figure S2). Specifically, data regarding model utilization frequencies were derived from a systematic search of PubMed and Web of Science databases covering the period from 2000 to 2024, conducted in accordance with PRISMA guidelines. Search queries combined “spinal cord injury” with keywords including “contusion,” “compression,” “transection,” “ischemia,” and “crush.” From an initial yield of 8694 records, 1096 were excluded based on title/abstract screening (exclusion criteria included: non‐English literature, in vitro studies, reviews, and clinical trials). Following full‐text review, 6055 primary animal studies met our inclusion criteria, which required explicit reporting of animal species, trauma type, spinal segment, and injury stage. To minimize redundancy, multiple publications by the same research group utilizing the identical model setup were counted as a single entry. Statistical results indicate that mice and rats are most frequently subjected to contusion models; guinea pigs are often used for compression models; rabbits for ischemic models; cats and dogs primarily for compression models; pigs commonly for ischemic models; and NHPs and zebrafish predominantly for transection models (Figure 1). The core objective of these models is to replicate the injury mechanisms of specific clinical scenarios at a physical and macropathological level through controlled experimental means—that is, to pursue a simulation of the physical form of human injury. To elucidate the specific applications, advantages, and inherent limitations of each tool, we have functionally reorganized these models according to the key clinical scenarios they simulate (Figure S3). Quantitative analysis of preclinical model utilization: a data‐driven imbalance. The pie charts illustrate the distribution of common SCI models utilized across nine key species, based on a comprehensive literature search from 2000 to 2024. Percentages are accompanied by the absolute number of studies (N) for rigorous interpretation. Specifically, in rabbits (total N = 193), the most common SCI model is ischemic injury, accounting for 91% (n = 175), while transverse injury accounts for 4% (n = 8), contusion injury for 4% (n = 8), and crush injury for 1% (n = 2). In mice (total N = 1263), the most common SCI model is contusion injury, accounting for 35% (n = 442), followed by compressive injury at 17% (n = 215), transverse injury at 18% (n = 227), crush injury at 9% (n = 114), and ischemic injury at 21% (n = 265). In rats (total N = 3784), the most common SCI model is contusion injury at 36% (n = 1362), with transverse injury at 21% (n = 795), compressive injury at 21% (n = 795), crush injury at 5% (n = 189), and ischemic injury at 17% (n = 643). For guinea pigs (total N = 76), the most common SCI model is ischemic injury at 39% (n = 30), followed by transverse injury at 9% (n = 7), contusion injury at 24% (n = 18), and crush injury at 28% (n = 21). In cats (total N = 20), the most common SCI model is compressive injury at 55% (n = 11), with transverse injury at 45% (n = 9). For dogs (total N = 467), the most common SCI model is compressive injury at 38% (n = 177), followed by transverse injury at 22% (n = 103), contusion injury at 6% (n = 28), and ischemic injury at 34% (n = 159). In pigs (total N = 152), the most common SCI model is ischemic injury at 39% (n = 59), with compressive injury at 34% (n = 52), transverse injury at 3% (n = 5), contusion injury at 22% (n = 33), and crush injury at 2% (n = 3). For primates (total N = 50), the most common SCI model is transverse injury at 62% (n = 31), with contusion injury at 30% (n = 15) and ischemic injury at 8% (n = 4). Finally, in zebrafish (total N = 50), the most common SCI model is transverse injury at 90% (n = 45), followed by crush injury at 10% (n = 5). Simulating Acute Closed Trauma: Replicating Instantaneous Violent Injury Acute closed trauma, such as that resulting from traffic accidents or falls from height, is the most common clinical type of SCI. Its pathological core is a complex cascade of secondary injuries triggered by an instantaneous mechanical force [18, 19, 20]. The contusion model, which applies a rapid and transient impact to the spinal cord via a weight‐drop or a precisely controlled impactor device, is the primary tool for simulating this type of trauma [21]. It excels at recapitulating the complex pathological processes following acute injury and holds high clinical relevance, making it widely used for studying mechanisms in the acute and subacute phases and helping researchers understand post‐injury responses and recovery [21, 22, 23, 24, 25]. By adjusting factors such as impact weight, height, and velocity, researchers can precisely control the severity of the injury. This enables the rapid evaluation of the efficacy of new treatments and interventions and aids in the identification of effective drugs or therapeutic strategies [26, 27, 28, 29, 30]. The model accurately reflects the SCI mechanisms encountered in clinical settings, thereby facilitating the translation of research findings into clinical applications [31, 32]. However, a limitation is that while it allows for the swift assessment of short‐term outcomes, the long‐term effects on functional recovery may require further investigation using other models [33]. For these reasons, the contusion model is predominant in rodent studies, representing the most frequently used model in both mice (35%) and rats (36%) (Figure 1). This heavy reliance on rodents, however, masks the central flaw of the current paradigm. The model's simulation of physical form creates a translational trap by ignoring the profound biological mismatches that determine outcomes. First, the inflammatory dynamics diverge starkly: in rats, neutrophil infiltration peaks at 6 h post‐injury, whereas in mice, it is delayed and sustained, peaking between 3 and 14 days [34, 35]. An immunomodulatory drug targeting this acute 6‐h window, validated in rats, may fail to capture the optimal therapeutic window in mice, severely complicating its extrapolation to humans. Second, the reparative microenvironment is fundamentally different: rats tend to form cystic cavities, which are pathologically analogous to chronic human SCI, while mice develop a dense, fibrotic scar [13, 36]. A regenerative strategy (e.g., a biomaterial scaffold) designed to fill a cavity (rat) would be ineffective against a dense physical barrier (mouse). Thus, the field's two most common models yield contradictory data on the two most critical therapeutic targets: inflammation and scarring. Simulating Chronic Compressive Injury: A Unique Window Into Slow Pathological Progression Chronic compression, arising from conditions such as intervertebral disc herniation, epidural tumors, or spinal stenosis, involves a relatively slow injury process with progressive pathological changes. This provides a unique window for studying chronic‐phase pathology and endogenous repair mechanisms [37, 38]. The compression model, which induces injury by applying sustained pressure to the spinal cord with a specialized device, is particularly effective for simulating clinically common closed injuries like those caused by disc herniation or tumor encroachment [39, 40, 41, 42, 43]. By adjusting the applied pressure and duration, researchers can systematically control the injury severity, which facilitates the evaluation of different therapeutic approaches [44, 45]. A potential limitation, however, is its inability to fully recapitulate the complexities of other injury types, such as transection or ischemic injuries. The compression model is especially common in studies involving larger animals, such as cats (55%) and dogs (38%) (Figure 1). Additionally, the crush model induces injury by applying a brief but sustained compressive force to the spinal cord using calibrated forceps [46, 47, 48, 49, 50]. This model effectively simulates clinical scenarios of spinal cord compression caused by tumors, hematomas, or other pathological states that exert persistent pressure [51, 52]. In chronic‐phase studies, the crush model is valuable for analyzing responses related to neuro‐regeneration and repair [53, 54, 55]. It is well‐suited for long‐term observation, allowing for the assessment of various interventions and functional recovery, thereby providing deep insights into the pathological processes of chronic injury [56, 57]. A key limitation, however, is that while it effectively mimics compression, it may not fully represent the complex injury mechanisms initiated by other insults, such as transection [58]. While these models are valuable for studying chronic pathology, their translational value for functional recovery is often overestimated. The assessment of recovery in quadrupedal animals (rodents, cats, dogs) relies heavily on gross locomotor scoring (e.g., BBB score). This approach overlooks the fundamental neuroanatomical differences in the corticospinal tract (CST) [59]. These species largely lack the direct, monosynaptic CST‐to‐motor‐neuron connections that are the anatomical basis for fine, independent motor control in humans [60]. Therefore, recovery observed in these models may rely on compensatory mechanisms or reorganization of circuits that are simply not present in primates, severely limiting their predictive power for human functional restoration. Simulating Penetrating and Complete Injuries: Establishing a Platform for Regeneration Research Although clinically less common, penetrating injuries or complete spinal cord transection resulting from stab wounds or severe fractures hold an indispensable role in basic research due to their unique injury characteristics [61, 62, 63, 64]. The transection model involves the partial (hemi‐section) or complete severing of the spinal cord using microsurgical instruments [65, 66, 67, 68]. Characterized by a complete disruption of cord continuity, this model simulates severe clinical SCI scenarios, including catastrophic trauma or surgical mishaps [69, 70, 71, 72]. The primary objective of the transection model is to investigate the pathophysiological changes and repair mechanisms following the complete severance of the spinal cord. Given its definitive and severe nature, the transection model is ideal for studying axonal regeneration. It allows researchers to conduct long‐term observations postinjury, assess the efficacy of different therapeutic strategies, and evaluate the recovery of spinal cord function, making it highly suitable for chronic‐phase studies [62, 73, 74, 75]. Its main limitation, however, is that the total loss of function resulting from complete transection differs significantly from that of partial or compressive injuries. Consequently, the model may not effectively reflect the injury and recovery processes associated with partial or less severe trauma [63]. For this reason, the model is extensively used in species where the entire regenerative process can be clearly observed, such as NHPs (62%) and zebrafish (90%), the latter of which possesses a robust regenerative capacity (Figure 1). The high prevalence of this model in NHPs (62%) is a direct acknowledgment of these innate differences in neural circuit anatomy. Unlike rodents, primates possess an extensive, direct monosynaptic CST that innervates ventral horn motor neurons, a feature essential for fine motor control (e.g., independent hand movements) [60]. Therefore, for any therapy aiming to restore clinically relevant fine motor function, validation in an NHP model is not optional‐it is the only model that possesses the requisite anatomical fidelity to test the hypothesis. Studies in rodents, while useful for mechanistic discovery of regeneration, cannot predict this specific functional outcome. Simulating Vasculogenic Injury: Focusing on Ischemia‐Induced Secondary Damage In addition to direct mechanical trauma, the interruption of spinal cord blood supply resulting from aortic surgery complications, vascular malformations, or thrombosis constitutes another distinct etiology of SCI [76, 77, 78]. The ischemic model induces injury by blocking the blood supply to the spinal cord [79, 80, 81]. This is typically achieved by transiently clamping the thoracoabdominal aorta or key arteries supplying the spinal cord, thereby causing ischemia–reperfusion injury to a specific region [82, 83, 84]. The ischemic SCI model simulates clinical scenarios of interrupted spinal cord blood flow, such as that caused by vascular occlusion, aneurysm rupture, or surgical interference [85, 86, 87]. The primary purpose of the ischemic model is to investigate the pathophysiological changes and repair mechanisms within the spinal cord under ischemic conditions [88, 89, 90, 91]. The model is particularly valuable for studying the secondary neuronal injury mechanisms triggered by ischemia, such as oxidative stress, inflammatory responses, and cell death. This makes it a unique and indispensable tool for developing vasculo‐protective and anti‐ischemic drugs [88, 92]. However, like their mechanical trauma counterparts, these models are subject to the same translational chasm in inflammatory dynamics (Weapon A). The cellular and temporal profile of immune infiltration (e.g., neutrophils, macrophages) and microglial activation following ischemia–reperfusion is highly species‐specific [93, 94]. An immunomodulatory drug validated in a rabbit model, which dominates this category (91%), may target a therapeutic window or cellular cascade that does not align with that in human pathology, again highlighting the limitations of relying on a single‐species, single‐model validation approach (Figure 1). However, while the ischemic model faithfully recapitulates the hemodynamics of vascular occlusion, the species‐specific divergence in inflammatory kinetics imposes an intrinsic biological limitation on the precise definition of the therapeutic window—the decisive factor for the clinical efficacy of neuroprotective interventions. In summary, while the aforementioned models (contusion, compression, transection, and ischemia) are indispensable for mirroring the distinct biomechanical and physical triggers of SCI, they share a profound anatomical caveat. The evaluation of fine motor recovery in quadrupedal models is universally confounded by the absence of direct, monosynaptic corticospinal projections—the primary anatomical substrate for human dexterity. This inherent validity ceiling, along with other critical interspecies divergences, dictates that simulating physical form is insufficient for clinical translation. We will systematically dissect these biological chasms in the following section. Interspecies Pathophysiological Differences as the Root of Translational Failure Although animal models of SCI successfully simulate the physical morphology of human trauma, the systemic failure of clinical translation reveals a more profound obstacle [95]. This barrier lies in the deep‐seated differences between species in the key biological responses that ultimately determine therapeutic success [13]. A substantial body of evidence indicates that these cross‐species pathophysiological chasms constitute the fundamental reason for translational research failure [14, 34, 35]. We will systematically dissect these differences from three core perspectives: inflammatory dynamics, the reparative microenvironment, and neuroanatomy (Figure 2). The three pillars of translational failure: interspecies gaps in immunodynamics, microenvironment, and neuroanatomy. This figure illustrates differences between rodent (rat/mouse) and human SCI across three key domains that impede clinical translation. Inflammatory dynamics mismatch: Significant discrepancies exist in the timeline of inflammatory cell (e.g., neutrophil and T cell) infiltration in rodents (e.g., neutrophil peak at 6 h in rats vs. 7–14 days in mice), which hinders the translation of immunomodulatory therapies. Repair microenvironment (cavity vs. scar): Rats tend to form cystic cavities, whereas mice develop dense fibrotic scars, the latter of which is pathologically more akin to human chronic SCI. This structural difference has led to translational failures for regenerative strategies. Neural circuitry (indirect vs. direct): Rodents primarily rely on indirect CST control, whereas humans and NHPs possess direct (monosynaptic) CST control that is critical for fine motor function. This anatomical difference impedes the translation of functional recovery strategies. The Temporal Mismatch in Inflammatory Dynamics The temporal mismatch in postinjury inflammatory dynamics is a primary reason for the translational failure of immunomodulatory therapies. Rats and mice, the most commonly used SCI models, exhibit starkly different patterns of immune cell infiltration. In the rat contusion model, neutrophil infiltration peaks at 6 h postinjury and rapidly subsides within 48 h [35]. In mouse models, however, neutrophil numbers continue to increase, reaching their peak only between 3 and 14 days postinjury [34]. T‐cell infiltration shows a similarly significant delay: it occurs between 3 and 7 days in rats, whereas in mice, T‐cells are not detected until 14 days postinjury [14]. This fundamental difference in immunodynamics directly invalidates the therapeutic window across species. A drug designed to target acute‐phase (6‐h) neutrophil infiltration, proven effective in a rat model, is almost certainly doomed to fail if directly applied to a mouse model or extrapolated to humans, as it would miss the optimal window for intervention. Crucially, clinical neuropathological studies indicate that human SCI exhibits a distinct and more protracted inflammatory chronobiology. In human patients, neutrophil infiltration typically begins within hours but reaches its peak between 1 and 3 days postinjury, persisting for several weeks, while robust macrophage accumulation peaks at later stages (weeks to months) [96]. Consequently, neither the rapid, transient response in rats nor the significantly delayed onset in mice perfectly recapitulates the human condition; rather, the human inflammatory profile falls between these two rodent extremes while displaying a uniquely prolonged chronicity. This profound discrepancy dictates that relying exclusively on murine timelines to define clinical therapeutic windows is precarious. It further substantiates our argument that validation in large animal models (such as porcine models), which share closer immunological and temporal homology with humans, is an indispensable step before clinical translation. Structural Differences in the Postinjury Reparative Microenvironment Structural differences in the postinjury reparative microenvironment physically dictate the success or failure of regenerative medicine strategies. In the chronic phase, the lesion core in rats tends to liquefy, forming a cystic cavity that is pathologically similar to chronic human SCI [36, 97]. Conversely, the lesion core in mice predominantly becomes filled with a dense, fibrotic scar tissue rich in fibronectin and collagen, creating a physical barrier [13, 14]. While these phenotypes represent a biological spectrum rather than a strict dichotomy, the translational value lies in selecting the species that maximally recapitulates the specific pathological feature targeted by the therapy. Clinically, human SCI manifests as a heterogeneous, mixed phenotype comprising both cystic cavitation and dense fibrotic scarring. Quantitative neuropathological and advanced neuroimaging studies reveal that macroscopic cystic cavitation develops in approximately 50%–70% of severe human SCI cases, whereas dense fibrotic and glial scarring is virtually ubiquitous (nearly 100%) at the lesion epicenter or margins [98]. Therefore, rather than presenting “diametrically opposed” contradictions, these species‐specific divergences represent distinct facets of the complex human pathology. It is inaccurate to designate either species as the superior surrogate; instead, the rat model faithfully recapitulates the cystic component, while the mouse model mirrors the fibrotic barrier. This reality dictates that therapeutic evaluation must be mechanism‐specific: a strategy designed to fill a cystic void (rat‐appropriate) faces a fundamentally different physical challenge than one aiming to degrade a dense fibrotic matrix (mouse‐appropriate). Consequently, the selection of an animal model must be rigorously aligned with the specific pathological feature targeted by the intervention—cavity bridging versus scar modulation—rather than relying on a single species to represent the totality of human injury. Innate Differences in Neural Circuit Anatomy While the reparative microenvironment dictates the structural potential for axonal regrowth, the ultimate realization of function is governed by the wiring diagram itself. Here, innate differences in neuroanatomy fundamentally limit the translatability of rodent models in studies of functional recovery. The projection patterns of the CST, which is responsible for fine motor control, exhibit fundamental differences across species [59]. In rodents, the CST primarily projects to the dorsal horn of the spinal cord, indirectly modulating motor neurons [59]. In primates, including humans, however, the CST forms extensive monosynaptic connections that directly innervate motor neurons in the ventral horn. This anatomical feature is the basis for higher‐order functions such as fine, independent hand movements [59, 60]. This implies that the neural circuit reorganization underlying motor recovery observed in rodents may be entirely different from the mechanisms in humans. Consequently, while rodent models are invaluable for decoding propriospinal relay formation and plasticity‐mediated recovery, they possess an intrinsic validity ceiling for validating therapies specifically aiming to restore direct corticomotoneuronal control essential for human dexterity. The Solution: Implementing the MFM Framework Given the profound chasm between the simulation of physical form and the reality of interspecies pathophysiological differences, the conventional one therapy, one model mindset of single‐point validation is no longer tenable. To systematically bridge this translational gap, we introduce the MFM framework. This paradigm posits that translational success depends not on finding a single universally valid surrogate, but on rigorously aligning the specific mechanism of action of a therapy with the biological feature of highest fidelity in a given model. Operationalizing MFM requires a departure from indiscriminate testing toward a structured matrix comprising two core strategies: problem‐driven model selection and a hierarchical cross‐species validation pathway (Figure 3). The mechanistic fidelity matching framework: integrating problem‐driven model selection with a hierarchical cross‐species validation pipeline. This schematic proposes a new framework to overcome the SCI translational “valley of death,” replacing the traditional “single‐point validation” (indicated by an “X” at the top). This framework comprises two core strategies. Question‐driven model selection (left panel): This emphasizes matching key biological features (e.g., fibrotic scarring) with specific therapeutic goals (e.g., anti‐fibrosis) to select the optimal model (e.g., mice for scar validation, primates for functional validation). Cross‐species validation pathway (right panel): This proposes a progressive three‐phase workflow: Phase 1 (mechanism exploration, e.g., mice), Phase 2 (efficacy validation, e.g., rats), Phase 3 (translational confirmation, e.g., NHPs), to systematically confirm efficacy, safety, and clinically relevant function. This integrated strategy aims to identify therapeutic candidates with clinical translation potential. Strategy 1: Problem‐Driven, Precise Model Selection The cornerstone of this new paradigm is a shift from model‐driven to problem‐driven, precise model selection. The core mechanism of a given therapeutic strategy must be matched with the most relevant biological characteristic of the animal model. For instance, when developing antifibrotic and matrix‐remodeling strategies, the mouse model is superior. Because its lesion core is prone to forming a dense, fibrotic scar, it offers a more stringent and therefore more translationally valuable platform for validating therapies designed to inhibit scar formation [13]. Conversely, for therapies targeting functional recovery, particularly of fine motor control, ultimate validation in NHP models is indispensable. Only their CST anatomy and functional control patterns are sufficiently homologous to those of humans to provide effective predictive value for translation, especially for interventions aimed at restoring functions like hand dexterity [59, 60]. Strategy 2: A Multispecies, Multimodel Cross‐Validation Pathway For a therapy to have a genuine potential for successful translation, its preclinical evidence chain must be reproducible across species, ensuring its efficacy is not contingent on the unique biological context of a single model. Here, we propose a strategic hierarchy, progressive cross‐validation pathway designed to systematically filter out false‐positive results. Crucially, this comprehensive validation need not be achieved by a single laboratory in isolation; rather, it should become a collective community standard for advancing candidate therapies to clinical trials. By leveraging multicenter collaborations and specialized core facilities, the field can distribute the burden of this rigorous pipeline. In the mechanistic exploration phase, the rich genetic tools available in mouse models should be leveraged to establish proof‐of‐concept at the molecular and cellular levels, definitively identifying the drug target and its mechanism of action. In the efficacy validation phase, the therapy should be advanced to rat models, where pathological features (such as cystic cavity formation) and behavioral assessment paradigms are more established. This stage serves as a crucial replication of the core therapeutic efficacy. In the translational confirmation phase (large animal validation), for therapies that demonstrate robust effects in both preceding stages, a final confirmation of efficacy, safety, dosage, and the therapeutic window is mandatory. This phase demands a differentiated approach: Porcine models provide a critical intermediate bridge, offering spinal cord dimensions and immune systems that approximate human physiology more closely than rodents while presenting a more economically and ethically accessible option for validating anti‐inflammatory agents or biomaterial scaffolds. However, for interventions specifically targeting the restoration of fine motor dexterity, NHPs remain the indispensable standard due to their unique direct corticospinal projections. Only by adhering to such a rigorous, multidimensional assessment paradigm can we screen for therapies that genuinely possess the potential to cross the valley of death, bringing tangible hope for an eventual cure for SCI. Perspectives To bridge the chasm between animal models and human pathology in preclinical SCI research, a paradigm shift from morphological mimicry to mechanistic approximation is imperative. The current reliance on single, flawed models has become a bottleneck for translational medicine; we must therefore pivot to a multidimensional research roadmap. The core of this new approach involves three key initiatives: constructing a cross‐species, quantitative pathological atlas to serve as a biological frame of reference; proactively engineering a new generation of more precise models; and revolutionizing preclinical assessment standards to prioritize mechanism‐based, objective biomarkers (Figure 4). The future of SCI translation: integrating humanized models, multiomic atlases, and mechanism‐coupled biomarkers. The upper panel illustrates the current translational bottleneck resulting from an over‐reliance on single animal models that prioritize physical simulation over biological fidelity. To bridge this chasm, the schematic outlines a multidimensional research roadmap comprising three key initiatives. Pillar 1 (center): the construction of a cross‐species pathological reference atlas. This leverages high‐dimensional data (e.g., transcriptomics) and AI to systematically compare human and animal SCI, establishing a multiscale biological frame of reference to identify translatable targets. Pillar 2 (left): proactively engineering precise models. This shifts from passive selection to active design, utilizing CRISPR humanization to simulate human immune responses and in vitro organoids to recapitulate human‐specific scar formation and neural circuitry. Pillar 3 (right): redefining preclinical gold standards. This replaces subjective behavioral scoring with objective, mechanism‐coupled readouts, including advanced neuroimaging for tissue structure, electrophysiology for circuit function, and cross‐species validated liquid biopsy biomarkers. The bottom panel depicts the ultimate outcome: a new era of precise translation where therapies are validated by objective indicators to ensure clinical success. First, establishing a quantitative, cross‐species pathological reference atlas is the cornerstone of achieving precise translation. However, this effort must transcend the simple enumeration of cell types. We urgently need to leverage cutting‐edge technologies, such as spatial transcriptomics, to systematically dissect the spatial heterogeneity of the lesion microenvironment. A critical focus must be placed on the lesion border zone—the interface where regeneration succeeds or fails—to determine if the cellular neighborhoods and interactome networks in this region are evolutionarily conserved or divergent between rodents and humans. Furthermore, we propose a frontier shift toward the development of AI‐driven computational translation models (in silico modeling). By feeding these high‐dimensional cross‐species datasets into machine learning algorithms, we can move beyond qualitative comparison to algorithmic calibration. This would enable researchers to mathematically project how a therapeutic signal observed in the murine biological context would manifest in human physiology, effectively creating a computational bridge to predict clinical efficacy before trials begin. Second, we must shift from passively selecting models to proactively engineering new models that more closely approximate human pathology. This requires the deep integration of gene‐editing and tissue‐engineering technologies. For example, using CRISPR to perform humanization modifications on key genes can create humanized mice that simulate human‐specific immune responses. Alternatively, assembloid in vitro models, built from organoids, can be used to more faithfully recapitulate the features of human scar formation and neural circuitry. Finally, redefining the gold standard for preclinical research is critical to ensuring translational success. We must break our over‐reliance on behavioral scoring, as these outcomes are highly susceptible to interference from species‐specific compensatory mechanisms. Future efficacy validation must integrate a suite of objective, quantifiable assessment tools. These should include the use of advanced neuroimaging to evaluate tissue structure, electrophysiology, and optogenetics to assess circuit function, and the development of cross‐species‐validated liquid biopsy biomarkers. Only when a therapy demonstrates reproducible, positive effects across these mechanistic indicators can we have genuine confidence in its potential for clinical translation. In conclusion, the value of preclinical inquiry lies not in isolating successful outcomes in murine models, but in forecasting clinical translatability. The implementation of the MFM framework allows us to deconstruct the fidelity paradox by matching specific therapeutic mechanisms to the species with the highest biological relevance. Consequently, evolutionary divergences are repurposed from confounding variables into a stratified validation matrix, thereby bridging the translational gap with genuine clinical candidates. Author Contributions L.C. and M.X. conceived and designed the study. L.C., W.P., and Y.Z. analyzed the data and finalized the figures. L.C. wrote the manuscript. M.X. and V.Y. contributed to the paper re‐edit. All the authors revised and approved the final version of the manuscript. Funding This work was supported by grants from Natural Science Foundation of Henan (262300421603); Henan Province Medical Science and Technology Research Program (SBGJ202403031); Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (GZC20232401); Hunan Provincial Natural Science Foundation (2023JJ40572); National Natural Science Foundation of China (U25A2065, 82071331); Canadian Institutes of Health Research (VWY). Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Pathological mechanisms of SCI. Figure S2: Preparation methods for spinal cord models in different animals. Figure S3: Advantages and disadvantages of different SCI preparation methods.